

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM396097

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE AND REASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY INTERESTS

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Unicredit Bank AG, New York Branch as secured party in possession of the assests of Hilco Financial LLC		08/18/2014	Corporation: GERMANY

RECEIVING PARTY DATA

Name:	Humanetics Corporation
Street Address:	7650 Edinborough Way
Internal Address:	Suite 620
City:	Edina
State/Country:	MINNESOTA
Postal Code:	55435
Entity Type:	Corporation: MINNESOTA
Name:	AdvantRx Corporation
Street Address:	7650 Edinborough Way
Internal Address:	Suite 620
City:	Edina
State/Country:	MINNESOTA
Postal Code:	55435
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 13

Property Type	Number	Word Mark
Registration Number:	2476865	WEIGHT LOSS ACCELERATOR
Registration Number:	2607975	METABOLIC MIRACLE
Registration Number:	2675783	7-KETO
Registration Number:	2724792	HUMANETICS THE SCIENCE OF SUPPLEMENTS
Registration Number:	2942298	HUMANETICS THE SCIENCE OF SUPPLEMENTS.
Registration Number:	2964802	7-KETO
Serial Number:	77057271	AUGMUNE
Registration Number:	2381825	INZITOL
Registration Number:	2533058	ADVANTRX

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	2748661	ADVANTRX FEEL THE ADVANTAGE!
Registration Number:	2780616	ADVANTRX
Registration Number:	2783263	DUOLIEF
Registration Number:	2887075	NEUTROBLOC

CORRESPONDENCE DATA

Fax Number: 2123108007
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 6467284147
Email: Juan.Arias@weil.com
Correspondent Name: Juan Arias
Address Line 1: Weil, Gotshal & Manges LLP
Address Line 2: 767 Fifth Avenue
Address Line 4: New York, NEW YORK 10153

NAME OF SUBMITTER:	Juan Arias
SIGNATURE:	/Juan Arias/
DATE SIGNED:	08/23/2016

Total Attachments: 16
source=IP Release#page1.tif
source=IP Release#page2.tif
source=IP Release#page3.tif
source=IP Release#page4.tif
source=IP Release#page5.tif
source=IP Release#page6.tif
source=IP Release#page7.tif
source=IP Release#page8.tif
source=IP Release#page9.tif
source=IP Release#page10.tif
source=IP Release#page11.tif
source=IP Release#page12.tif
source=IP Release#page13.tif
source=IP Release#page14.tif
source=IP Release#page15.tif
source=IP Release#page16.tif

**RELEASE AND REASSIGNMENT
OF INTELLECTUAL PROPERTY SECURITY INTERESTS**

This RELEASE AND REASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY INTERESTS is made as of August 18, 2014 and granted by Unicredit Bank AG, New York Branch ("Secured Party") as secured party in possession of the assets of Hilco Financial LLC ("Lender").

WHEREAS, Lender entered into a certain Credit Agreement dated March 12, 2007 ("Credit Agreement") with Humanetics Corporation, a Minnesota corporation ("Humanetics") and AdvantRx Corporation, a Delaware corporation ("AdvantRx") (collectively "Borrowers") pursuant to which Borrowers executed and delivered a General Security Agreement dated March 12, 2007 ("General Security Agreement") wherein Borrowers granted a security interest to Lender in, among other things, certain Patents (as defined in the General Security Agreement) and certain Trademarks (as defined in the General Security Agreement) as security for certain obligations owing by Borrowers to Lender, including specifically but not exclusively the Patents set forth on Schedule A and the Trademarks set forth on Schedule B hereto; and

WHEREAS, pursuant to the Credit Agreement and the General Security Agreement Humanetics executed and delivered a Patent Security Agreement dated March 12, 2007 ("Humanetics Patent Security Agreement") and a Trademark Security Agreement dated March 12, 2007 ("Humanetics Trademark Security Agreement"); and

WHEREAS, the Humanetics Patent Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on April 5, 2007 at Reel/Frame 019116/0641; and

WHEREAS, the Humanetics Trademark Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on April 5, 2007 at Reel/Frame 3516/0280; and

WHEREAS, pursuant to the Credit Agreement and the General Security Agreement AdvantRx executed and delivered a Patent Security Agreement dated March 12, 2007 ("AdvantRx Patent Security Agreement") and a Trademark Security Agreement dated March 12, 2007 ("AdvantRx Trademark Security Agreement"); and

WHEREAS, the AdvantRx Trademark Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on April 5, 2007 at Reel/Frame 3516/0293; and

WHEREAS, pursuant to a Secured Party Bill of Sale dated August 4, 2009 ("Secured Party Bill of Sale"), Secured Party purchased all right, title and interest of Lender in and to the General Security Agreement, the Humanetics Patent Security Agreement, the Humanetics Trademark Security Agreement, the AdvantRx Patent Security Agreement, and the AdvantRx Trademark Security Agreement; and

WHEREAS, pursuant to the Secured Party Bill of Sale Lender executed and delivered an Assignment of Patent Security Agreement dated January 26, 2012 ("Assignment of Patent Security Agreement") and an Assignment of Trademark Security Agreement dated January 26, 2012 ("Trademark Security Agreement"); and

WHEREAS, the Assignment of Patent Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on January 27, 2012 at Reel/Frame 027612/0709; and

WHEREAS, the Assignment of Trademark Security Agreement was recorded by the Assignment Division of the United States Patent and Trademark Office on January 27, 2012 at Reel/Frame 4706/0556

as to the Humanetics Trademark Security Agreement and at Reel/Frame 4706/0660 as to the AdvantRx Trademark Security Agreement; and

WHEREAS, Borrowers have requested that Secured Party release its security interest and reassign to Borrowers any and all right, title and interest that Secured Party may have in the intellectual property pursuant to the Credit Agreement, the Humanetics Patent Security Agreement, the AdvantRx Patent Security Agreement, the Assignment of Patent Security Agreement, the Humanetics Trademark Security Agreement, the AdvantRx Trademark Security Agreement, and the Assignment of Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Secured Part hereby releases its security interest in all of Borrowers' right, title and interest in and to all of the following (collectively "Released Intellectual Property").

Patents: All of Borrowers' patents and patent applications throughout the world, including without limitation the patents and patent applications listed in Schedule A hereto and all reissues, divisionals and continuations thereof ("Released Patents").

Trademarks: All of Borrowers' trademark applications and registrations throughout the world, including without limitation such trademark applications and registrations listed in Schedule B hereto, and all common law trademark rights, URLs and domain names throughout the world ("Released Trademarks").

Licenses: All licenses relating to any of the Released Patents and Released Trademarks and all income and royalties with respect to any such licenses.

Right to Sue: All rights to sue for past, present or future infringement of the Released Patents, and past, present or future infringement or dilution of Released Trademarks.

Secured Party hereby reassigns, grants and conveys to Borrower, without any representation, warranty, recourse or undertaking by Secured Party, all of Secured Party's right, title and interest in and to the Released Intellectual Property.

[Remainder of page left blank intentionally. Signature page follows.]


IN WITNESS WHEREOF, Secured Party has caused this Intellectual Property Release and Reassignment to be duly executed by its duly authorized officer as of the day and year first above written.

**UNICREDIT BANK AG, NEW
YORK BRANCH**

By: 

Name: Michael D. Novellino
Director

Title: _____

By: 

Name: THILO HUBER
Associate Director

Title: _____

HUMANETICS CORPORATION UNITED STATES PATENTS

REF	PATENT #	ISSUE DATE	TITLE
1.	4,897,390	January 30, 1990	Novel Anti-Obesity Compounds and Method of Use
2.	5,202,122	April 13, 1993	Process for Enhancing the Hypocholesterolemic Effect of Edible Pulp and the Product Obtained thereby
3.	5,245,095	September 14, 1993	Extrication of Carotenoids from Natural Sources
4.	5,292,730	March 8, 1994	Modulation of immune system with 5-Androstenes
5.	5,296,481	March 22, 1994	Treatment process for promoting weight loss employing a substituted 5-Androstene
6.	5,304,374	April 19, 1994	Process for Enhancing the Hypocholesterolemic Effect of Edible Pulp and the Product Obtained thereby
7.	5,354,851	October 11, 1994	Process for Producing Crude Pectin Through Ion Exchange
8.	5,403,612	April 4, 1995	Process for Producing a Phosphorylated Pectin-Containing Fiber Product
9.	5,424,463	June 13, 1995	5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss
10.	5,506,223	April 9, 1996	5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss
11.	5,510,551	April 23, 1996	Extraction of Carotenoids from Natural Sources
12.	5,585,371	December 17, 1996	Treatment of immune system with 5-Androstene

REF	PATENT #	ISSUE DATE	TITLE
13.	5,641,766	June 24, 1997	Up-regulation of immune system with 5-Androstenes
14.	5,707,983	January 13, 1998	Treatment of Alzheimer's disease and modulation of immune system with 5-Androstenes
15.	5,807,848	September 15, 1998	Use of DHEA-3-Carboxylates to Control Body Weight
16.	5,869,709	February 9, 1999	Process for effecting allylic oxidation
17.	5,885,977	March 23, 1999	Use of 5-Androstenes in the treatment of HIV wasting syndrome
18.	6,111,118	August 29, 2000	Process for effecting allylic oxidation
19.	6,153,606	November 28, 2000	Improving Memory by the Administration of 5-Androstene-3-Beta-ol-7, 17-Dione and 3 Beta Esters Thereof
20.	6,252,119	June 26, 2001	Copper-catalysed allylic oxidation using alkyl hydroperoxide
21.	6,372,732	April 16, 2002	Use of 5-Androstene 3-Beta-ol-7, 17-Dione in the Treatment of Lupus Erythematosus
22.	6,384,251	May 7, 2002	Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
23.	6,399,084	June 4, 2002	Method for diminishing wrinkles and fine lines of the skin by the topical application of 5-Androstene-3 β -ol-7, 17 Dione and metabolizable precursors thereof
24.	6,399,085	June 4, 2002	Method of moisturizing the skin by the topical application of 5-Androstene-3 β -ol-7, 17 Dione and metabolizable precursors thereof
25.	6,465,446	October 15, 2002	Treatment of dermatitis by the topical application of 5-Androstene-3 β -ol-7, 17 Dione and metabolizable precursors thereof
26.	6,489,313	December 3, 2002	Memory by the administration of 5-Androstene-3 β -ol-7, 17 dione and 3 β Esters Thereof

REF	PATENT #	ISSUE DATE	TITLE
27.	6,518,318	February 11, 2003	Stimulating Transport of Glucose into Animal Tissue by the Administration of Pinitol
28.	6,593,316	July 15, 2003	Use of $\Delta 5$ -Androstene- 3β -ol-7,17-dione in the Treatment of Lupus Erythematosus
29.	6,686,486	February 3, 2004	Process for Effecting Allylic Oxidation
30.	6,770,280	August 3, 2004	Treatment of Menorrhagia, Hypermenorrhea, Dysmenorrha and Menstrual Migraines by the Administration of Antibacterial Milk Product
31.	6,794,374	September 21, 2004	Use of $\Delta 5$ -Androstene- 3β -ol-7,17-dione in the Treatment of Arthritis
32.	6,924,274	August 2, 2005	Use of 5-Androstene- 3β -ol-7, 17 Dione in the Treatment of Lupus Erythematosus

HUMANETICS CORPORATION INTERNATIONAL PATENTS

REF	COUNTRY	NUMBER	DATE	TITLE
1.	Australia	647528	Aug 1, 1994	Treatment Process for Promoting Weight Loss Employing a Substituted 5-Androstene
2.	Canada	2,141,436	May 18, 1999	Treatment of Alzheimer's Disease and Modulation of Immune System with 5-Androstenes

REF	COUNTRY	NUMBER	DATE	TITLE
3.	Europe Austria Germany Spain France United Kingdom Italy Sweden	547151	Nov 20, 2002	Treatment Process for Promoting Weight Loss Employing a Substituted Δ 5-Androstene
4.	Europe Germany France England	0 746 322	Jan 19, 2000	Treatment of Alzheimer's Disease and Modulation of Immune System with 5-Androstenes
5.	Europe Germany Spain Italy United Kingdom France	0 666 746	May 25, 2001	5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss
6.	Japan	2973031	Sept 3, 1999	Treatment Process for Promoting Weight Loss Employing a Substituted 5-Androstene
7.	Japan	2762315	Mar 27, 1998	Therapeutic Agents Containing 5-Androstene for Treating Alzheimer's Disease and for Modulating Immune Systems
8.	Japan	3143749	Jan 5, 2001	5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss

REF	COUNTRY	NUMBER	DATE	TITLE
9.	Europe Germany United Kingdom	1123100	Mar 2, 2005	Improving Memory by the Administration of Δ^5 -Androstenes- 3β -ol-7,17-Dione and 3 Esters Thereof
10.	Australia	2004200067	Nov 25, 2005	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal (7-oxo DHEA)
11.	PCT	US2004/000 541	Jan 12, 2004	Method of Achieving Accelerated Fat Loss by Administration of a Fat Loss Accelerating Agent to a Dieting Mammal (7-oxo DHEA)

HUMANETICS CORPORATION UNITED STATES PATENT APPLICATIONS

REF	SERIAL NO.	TITLE
1.	09/611,762	Increasing Biological Wellness Ratio
2.	10/340,980 Notice of Allowance	Method of Modulating Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent (7-oxo DHEA)
3.	10/755,251	Method of Achieving Accelerated Weight Loss by Administration of a Weight Loss Accelerating Agent to a Dieting Mammal (AET)
4.	10/755,525	Method of Modulating Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal (AET)

REF	SERIAL NO.	TITLE
5.	10/755,522	Method of Achieving Accelerated Fat Loss by Administration of a Fat Loss Accelerating Agent to a Dieting Mammal (AET)
6.	10/893,445	Composition Containing 7-oxo DHEA and Conjugated Linoleic Acid and Method of Promoting Weight Loss, Fat Loss and Modulation of Dieting Induced Change in Basal Metabolic Rate by Administration of the Composition
7.	10/433,043	Treatment of Chronic Fatigue Syndrome and Fibromyalgia Syndrome by the Administration of 5-Androstenes and Metabolizable Precursors Thereof (100 mg/day)
8.	10/541,780	Method of Achieving Accelerated Fat Loss by Administration of a Fat Loss Accelerating Agent to a Dieting Mammal [7-oxo DHEA]
9.	10/541,781	Method of Achieving Accelerated Weight Loss by Administration of a Weight Loss Accelerating Agent to a Dieting Mammal [7-oxo DHEA]
10.	11/570,903	Composition and Method for Promoting Weight Loss, Fat Loss or Modulation of Metabolic Rate (AdvantRX Formula)

HUMANETICS CORPORATION INTERNATIONAL PATENT APPLICATIONS

REF	COUNTRY	SERIAL NO.	TITLE
1.	Canada	2,090,759	Treatment Process Promoting Weight Loss Employing a Substituted Δ 5-Androstene
2.	Canada	2,148,373	Δ 5-Androstenes Useful for Promoting Weight Maintenance or Weight Loss and Treatment

REF	COUNTRY	SERIAL NO.	TITLE
3.	Europe	99104166.6	Treatment Process Promoting Weight Loss w/5-Androstenes
4.	Canada	2,276,783	Use of 5-Androstenes in the Treatment of HIV Wasting
5.	Europe	98902561.4-2123	Use of 5-Androstenes in the Treatment of HIV Wasting
6.	Hong Kong	00108409.8	Use of 5-Androstenes in the Treatment of HIV Wasting
7.	Canada	2,310,632	Use of Δ 5-Androstenes-3 β -ol-7,17-dione in Treatment of Lupus Erythematosus
8.	Canada	2,311,471	Use of Δ 5-Androstenes-3 β -ol-7,17-dione in the Treatment of Arthritis
9.	Canada	2344677	Improving Memory by the Administration of Δ 5-Androstene-3 β -ol-7,17-dione and 3 β Esters Thereof
10.	Japan	2000-576854	Improving Memory by the Administration of Δ 5-Androstene-3 β -ol-7,17-dione and 3 β Esters Thereof

REF	COUNTRY	SERIAL NO.	TITLE
11.	PCT	US2004/000537	Method of Achieving Accelerated Weight Loss by Administration of a Weight Loss Accelerating Agent to a Dieting Mammal (7-oxo DHEA)
12.	Canada	2,453,282	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal (7-oxo DHEA)
13.	Europe	04000543.1	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal (7-oxo DHEA)
14.	Japan	2004-4160	Method of Modulating the Basal Metabolic Rate of a Dieting Mammal by Administration of a Metabolic Modulating Agent to the Dieting Mammal (7-oxo DHEA)
15.	PCT	PCT/US2005/027518	Composition and Method for Promoting Weight Loss, Fat Loss or Modulation of Metabolic Rate
16.	Canada Notice of Allowance	2,374,269	Stimulating Transport of Glucose into Animal Tissue by the Administration of Pinitol

ADVANTRX CORPORATION UNITED STATES PATENTS

NONE

ADVANTRX CORPORATION INTERNATIONAL PATENTS

REF	COUNTRY	NUMBER	DATE	TITLE
1.	New Zealand	522317	Sept 9, 2004	A Combination of Pinitol and Creatine to Enhance Uptake and Retention of Creatine
2.	United Kingdom	2377639	Oct 13, 2004	A Combination of Pinitol and Creatine to Enhance Uptake and Retention of Creatine
3.	Australia	2001253598	April 13, 2006	A Combination of Pinitol and Creatine to Enhance Uptake and Retention of Creatine

ADVANTRX CORPORATION UNITED STATES PATENT APPLICATIONS

REF	SERIAL NO.	TITLE
1.	10/240,611	A Combination of Pinitol and Creatine to Enhance Uptake and Retention of Creatine

ADVANTRX CORPORATION INTERNATIONAL PATENT APPLICATIONS

REF	COUNTRY	SERIAL NO.	TITLE
1.	Canada	2,405,992	A Combination of Pinitol and Creatine to Enhance Uptake and Retention of Creatine

HUMANETICS CORPORATION TRADEMARKS AND SERVICE MARKS

REF	MARK	REG NUMBER	REG DATE
1.	WEIGHT LOSS ACCELERATOR	2,476,865	8/7/2001
2.	METABOLIC MIRACLE	2,607,975	8/13/2002
3.	7-KETO (and design)	2,675,783	1/21/2003
4.	HUMANETICS THE SCIENCE OF SUPPLEMENTS. (and design)	2,724,792	6/10/2003
5.	HUMANETICS THE SCIENCE OF SUPPLEMENTS. (and design)	2,942,298	4/19/2005
6.	7-KETO	2,964,802	7/5/2005

HUMANETICS CORPORATION INTERNATIONAL TRADEMARKS AND SERVICE MARKS

REF	COUNTRY	MARK	REG NUMBER	REG DATE
1.	Germany	KETOLIFE	397 53 018	07/14/1998
2.	France	KETOLIFE	97701689	04/10/1998
3.	Great Britain	KETOLIFE	2419679	10/30/1997
4.	Japan	KETOLIFE	4,278,310	05/28/1999
5.	Australia	7-KETO (and design)	778,504	02/16/2001

6.	Canada	7-KETO (and design)	606,108	03/24/2004
7.	Canada	7-KETO	594,851	11/17/2003
8.	Europe	7-KETO (and design)	992,909	02/14/2001
9.	Japan	7-KETO	4,328,255	10/22/1999
10.	Japan	7-KETO (and design)	4,371,847	03/31/2000

**HUMANETICS CORPORATION UNITED STATES TRADEMARK AND SERVICE
MARK APPLICATIONS**

REF	MARK	SERIAL NUMBER	FILING DATE
1.	AUGMUNE	77/057271	12/05/2006

**HUMANETICS CORPORATION INTERNATIONAL TRADEMARKD AND SERVICE
MARK APPLICATIONS**

NONE

ADVANTRX CORPORATION TRADEMARKS AND SERVICE MARKS

REF	MARK	REG NUMBER	REG DATE
1.	INZITOL	2,381,825	8/29/2000
2.	ADVANTRX	2,533,058	1/11/2002
3.	ADVANTRX FEEL THE ADVANTAGE!	2,748,661	8/5/2003
4.	ADVANTRX	2,780,616	11/4/2003
5.	DUOLIEF	2,783,263	11/11/2003
6.	NEUTROBLOC	2,887,075	9/21/2004

ADVANTRX CORPORATION INTERNATIONAL TRADEMARKS AND SERVICE MARKS

REF	COUNTRY	MARK	REG NUMBER	REG DATE
1.	Canada	INZITOL	647,273	9/6/2005

ADVANTRX CORPORATION UNITED STATES SERVICE MARK APPLICATIONS

NONE

ADVANTRX CORPORATION INTERNATIONAL SERVICE MARK APPLICATIONS

NONE